17,261 trials
Gastric Cancer · Chemotherapy Effect
Primary: Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour — 1; 0; 7; 11 Participants
Hepatocellular Cancer
Primary: Coagulation Zone Diameter-Short Axis — 36.0; 35.1 millimeters
Postoperative Ileus
Primary: Quality of Life After Surgery Based on Gastrointestinal Quality of Life Index (GIQLI) Global Score From Baseline to Visit 4. — -17.20; -10.10 score on a scale — p=>0.05
Depression · Major Depressive Episode · Bipolar Disorder
Primary: Hamilton Rating Scale for Depression, 24-Item (HRSD-24) — 22.625; 15.375 units on a scale
Influenza
Primary: Immune Response: Age 18-49 — 28.8; 21.3; 55.2; 45.0 Anti-body response (GMT)
Rhinitis,Allergic
Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale
Cocaine-Related Disorders
Primary: The Primary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment in the "Pre-qualified…
Cancer of the Breast
Primary: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression — 72.4 percentage of participants
Osteoarthritis, Knee
Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale
Plaque Psoriasis
Primary: Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) — 0; 29.4; 58.8; 66.7 percentage of participants — p=0.009
Carcinoma, Renal Cell
Primary: Probability Rates of Progression-free Survival at 9 Months — 0.431; 0.452 Probability — p=0.8531
Pancreatic Alpha Cell Carcinoma · Pancreatic Beta Islet Cell Carcinoma · Pancreatic Delta Cell Carcinoma
Primary: Determine the Maximum Tolerated Dose (MTD) of Temozolomide in Combination With 400 mg Pazopanib in Patients With Advanced Pancreatic Neuroendocrine Tumor (PNET) in Phase…
Soft Tissue Sarcoma
Primary: Phase 1b: Number of Subjects With Dose Limiting Toxicities (DLTs) — 0 Participants
Graft vs Host Disease · Malignancy
Primary: Percentage of Participants With Cumulative Incidence of Severe aGVHD at Day +100 Post-transplant — 6.8; 14.8; 2.2; 30.2 percentage of participants
COPD
Primary: Gas Trapping Measured During Washout of the Perfluorinated Gas Mixture. — 0.718; 0.541; 0.308; 0.451 percentage of total lung volume — p=<0.0001